Poland, June 23 -- Poland based Urtica Sp. z o.o. has secured contract from Gdanski Uniwersytet Medyczny for Pharmaceutical products Successful delivery of a medicinal product containing the active substance nivolumab as part of a non-commercial clinical trial Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma N-BRAVE . The value of the contract is worth 2639346900 PLN .
Published by HT Digital Content Services with permission from Pivotal Sources....